265 results
Page 2 of 14
8-K
EX-99.1
ai2s5 sc7
3 Nov 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
4:01pm
8-K
EX-99.2
1qgpum
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
EX-99.1
km455mlzy9gnsd12
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
EX-99.1
2um 8qmtw
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-10.1
r8pvau6g8 kf0gf
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
424B5
gi9faw7qo8y6vp43o027
5 Oct 23
Prospectus supplement for primary offering
10:47am
8-K
EX-99.1
1sjvca7rd li1gh
4 Oct 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
8:30am
8-K
EX-99.1
4hvwtv3 c8uc3mkvfu
3 Oct 23
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8:30am
8-K
EX-99.1
tlii5r
31 Aug 23
Kineta to Participate in Upcoming Investor Conferences
9:30am
8-K
EX-99.1
cpk0971 gk4bk
11 Aug 23
Regulation FD Disclosure
4:08pm
8-K
EX-99.1
xb43qi6wb fxi0bk1
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.1
751bk rmmlm
29 Jun 23
Kineta to Receive $5 Million Milestone Payment from Merck
7:01am
8-K
EX-99.1
an6l0g
28 Jun 23
Departure of Directors or Certain Officers
7:00am
424B3
srxq8crid
12 Jun 23
Prospectus supplement
5:01pm
8-K
EX-99.1
vzzcfemjrr5hve
9 Jun 23
Submission of Matters to a Vote of Security Holders
9:00am
8-K
EX-99.1
i5l8z9
24 May 23
Regulation FD Disclosure
9:30am
8-K
EX-99.1
dnrfnmims41s1
23 May 23
Kineta to Present at Jefferies Healthcare Conference
9:30am